Eli Lilly’s Trulicity (dulaglutide) Receives CHMP Recommendation for Label Update to Include Results from REWIND Study

 Eli Lilly’s Trulicity (dulaglutide) Receives CHMP Recommendation for Label Update to Include Results from REWIND Study

Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext to Develop Therapies for Autoimmune Disorders

Shots:

  • The EMA’s CHMP recommends an update to the Trulicity label and indication statement to include results from REWIND CV outcome study, demonstrating 12% reduction in MACE, reflecting both glycemic control and impact on CV events as fundamental considerations in patients with T2D
  • The REWIND study involves assessing of Trulicity (1.5mg, qw) + SOC vs PBO + SOC in 9,901 patients on CV risk with T2D from 24 countries, resulting in CV disease only in 31% patients while all had CV risk factor
  • Trulicity is the glucagon-like peptide-1 receptor agonist (GLP-1 RA), indicated to improve blood sugar (glucose) in adults with T2D (Mellitus) in adjunct to diet and exercise and is under EC’s review for approval in the EU

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post